Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells 24,474 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 24,474 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $9.04, for a total value of $221,244.96. Following the completion of the sale, the insider now directly owns 139,771 shares of the company’s stock, valued at $1,263,529.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Sera Prognostics Stock Down 3.8 %

Shares of Sera Prognostics stock traded down $0.36 on Thursday, hitting $9.10. The stock had a trading volume of 954,568 shares, compared to its average volume of 250,452. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $10.44. The company’s 50 day moving average price is $8.40 and its 200 day moving average price is $5.00.

Institutional Trading of Sera Prognostics

Institutional investors and hedge funds have recently made changes to their positions in the company. Frontier Wealth Management LLC acquired a new position in Sera Prognostics in the 1st quarter valued at about $30,000. Susquehanna International Group LLP acquired a new position in Sera Prognostics in the 1st quarter valued at about $39,000. Goldman Sachs Group Inc. acquired a new position in Sera Prognostics in the 1st quarter valued at about $41,000. Charles Schwab Investment Management Inc. acquired a new position in Sera Prognostics in the 1st quarter valued at about $46,000. Finally, Bank of New York Mellon Corp acquired a new position in Sera Prognostics in the 1st quarter valued at about $50,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.